Clinical Trial Detail

NCT ID NCT03155620
Title Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

Advanced Solid Tumor

lymphatic system cancer

central nervous system cancer

Therapies

Tazemetostat

Larotrectinib

LY3023414

Vemurafenib

Olaparib

Selumetinib

Ensartinib

Age Groups: adult child

Additional content available in CKB BOOST